Top Markets
#1 ADO Protocol ADO Protocol +194.72%
#2 Islamic Coin Islamic Coin +155.37%
#3 GoPlus Security GoPlus Security +40.11%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.15%
#6 TENDIES TENDIES +16.67%
#7 Wrapped NXM Wrapped NXM +14.87%
#8 Verus Coin Verus Coin +13.64%
#9 Tutorial Tutorial +13.32%
#10 Pons Pons +12.61%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Polydex Pharmaceuticals Limited Polydex Pharmaceuticals Limited

Polydex Pharmaceuticals Limited

POLXF
Rang in Aktien #33822
Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was... Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.
Aktienkurs
$1.99
Zuletzt synchronisiert: 2023-08-07
Marktkapitalisierung
$6.82M
Veränderung (1 Tag)
0.30%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Polydex Pharmaceuticals Limited (POLXF)

Kategorie

Healthcare
Gewinn für Polydex Pharmaceuticals Limited (POLXF)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Polydex Pharmaceuticals Limited betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Polydex Pharmaceuticals Limited von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE